• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Safety of Mechanical Thrombectomy for Acute Ischemic Stroke in Patients on Novel Oral Anticoagulants (P1.196)
Conclusion: Patients on NOAC undergoing mechanical thrombectomy show a trend towards increased sICH compared to the warfarin group. This may warrant larger studies of safety of mechanical thrombectomy in the presence of NOACs.Disclosure: Dr. Sharma has nothing to disclose. Dr. Atchaneeyasakul has nothing to disclose. Dr. Ziayee has nothing to disclose. Dr. Malik has nothing to disclose. Dr. Guada has nothing to disclose. Dr. Khandelwal has nothing to disclose. Dr. Ramdas has nothing to disclose. Dr. Yavagal has received personal compensation for activities with Covidien/evV3 as a consultant and Steering Committee Member.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Sharma, P., Atchaneeyasakul, K., Ziayee, H., Malik, A., Guada, L., Khandelwal, P., Ramdas, K., Yavagal, D. Tags: Acute Endovascular Therapy: Outcomes and Safety Source Type: research

Perihematomal Edema Expansion Rate Predicts Functional Outcome in Deep Intracerebral Hemorrhage (S31.008)
Conclusions: PHE72 predicts poor functional outcomes exclusively after deep ICH, whereas PHE24 predicts mortality for deep and lobar ICH.Disclosure: Dr. Grunwald has nothing to disclose. Dr. Urday has nothing to disclose. Dr. Beslow has nothing to disclose. Dr. Vashkevich has nothing to disclose. Dr. Ayres has nothing to disclose. Dr. Greenberg has received personal compensation for activities with Hoffman-Laroche. Dr. Goldstein has nothing to disclose. Dr. Battey has nothing to disclose. Dr. Simard has received royalty payments from Remedy. Dr. Rosand has nothing to disclose. Dr. Kimberly has received research support fro...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Grunwald, Z., Urday, S., Beslow, L., Vashkevich, A., Ayres, A., Greenberg, S., Goldstein, J., Battey, T., Simard, M., Rosand, J., Kimberly, W., Sheth, K. Tags: Stroke Risk, Outcomes, and Complications Source Type: research

Factors Influencing Oral Anticoagulant Prescribing Practices for Atrial Fibrillation among Cardiologists, Internists, and Vascular Neurologists (P1.227)
Conclusions: Medical specialties differ in their reasons for selecting NOACs over warfarin and in their use of aspirin with warfarin. Educational interventions may prevent misinterpretations of clinical trial results, particularly with regards to comparative efficacy in the prevention of ischemic stroke and intracerebral hemorrhage. Disclosure: Dr. Leung has nothing to disclose. Dr. Mcallister has nothing to disclose. Dr. Selim has nothing to disclose. Dr. Fisher has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Leung, L., Mcallister, M., Selim, M., Fisher, M. Tags: Cardiac Mechanisms and Complications of Stroke Source Type: research

Intracranial Hemorrhage on Warfarin: Time to Reversal Is of the Essence (I6.004)
Conclusions: We propose a "recommended reversal time" of less than 200 minutes for Vitamin K antagonists.Disclosure: Dr. Mehta has nothing to disclose. Dr. Jones has nothing to disclose. Dr. Ruiz Cuero has nothing to disclose. Dr. Wellwood has nothing to disclose. Dr. Rehman has nothing to disclose. Dr. Mitsias has nothing to disclose. Dr. Varelas has received personal compensation for activities with UCB Pharma as an advisory board member.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Mehta, C., Jones, M., Ruiz Cuero, M., Wellwood, J., Rehman, M., Mitsias, P., Varelas, P. Tags: Future Directions and Challenges in Stroke Team Action Therapy (STAT) Data Blitz Presentations Source Type: research

Antithrombotic Strategy in Cerebral Venous Thrombosis: Differences Between Neurologists and Haematologists in a Canadian Survey (P6.007)
Conclusions: In this cohort, there are differences between neurologists and hematologists with regards to initial choice of anticoagulant. It is possible that more complex presenting cases of CVT with concurrent venous infarction, hemorrhage or seizure may present to neurologists as compared to hematologists. Thus, an initial preference for UFH may reflect a desire for a reversible agent with a short half-life in the event of bleeding complications in an unstable patient. Our study is limited by response bias, though our response rate of 28[percnt] is comparable to other contemporary web-based physician surveys. The majori...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Alshimemeri, S., Camden, M.-C., Lui, G., Lee, A., Field, T. Tags: Cerebrovascular Disease and Interventional Neurology Poster Discussion Session Source Type: research

From 'Sweet Clover Disease' to NOACs: A Historical Perspective on Oral Anticoagulation for Prevention of Cardioembolic Stroke (P2.397)
CONCLUSIONS: Warfarin, born from ‘sweet clover disease’ and humble beginnings as rodenticide, has been the cornerstone of cardioembolic stroke prevention. Its shortcomings inspired the development of a new generation of oral anticoagulants.Disclosure: Dr. Chiota-McCollum has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Chiota-McCollum, N. Tags: History of Neurology Source Type: research

Antiphospholipid Syndrome-Associated Crescendo Stroke Events Treated with Rituximab (P4.351)
Discussion APS is an autoimmune condition associated with persistent antiphospholipid antibodies, characterised by thrombosis and pregnancy morbidity [1].Regarding APS and stroke the optimal antithrombotic agent, intensity of anticoagulation, and duration of treatment remains controversial[2]. Analysis of the APASS subgroup in the WARS study found aspirin and warfarin to be equally effective agents for secondary stroke prevention [2]. The majority of panel members at the International Congress on Antiphospholipid Antibodies recommended warfarin or combination aspirin and warfarin for patients with definite APS and arterial...
Source: Neurology - April 3, 2016 Category: Neurology Authors: O' Connor, A., Murphy, G., Cronin, S. Tags: Cerebrovascular Case Reports Source Type: research

Thrombosis at the Site of Pulmonary Venous Anastomosis Following Lung Transplantation Presenting with Multiple, Bilateral, Supra- and Infra-Tentorial Ischemic Strokes in the Setting of a Known Patent Foramen Ovale (P4.355)
CONCLUSIONS: PFO-related stroke risk over time remains a controversial matter and so does its prevention by closure, as there is no current evidence-based data to justify this procedure except on anecdotal basis. LT patients may represent a subset population who could benefit from pre-operative PFO screening and closure, especially if they have a history of prior strokes.Disclosure: Dr. Yeung has nothing to disclose. Dr. Bakhos has nothing to disclose. Dr. Biller has received personal compensation in an editorial capacity for the Journal of Stroke and Cerebrovascular Diseases, Frontier in Neurology and Up-To-Date.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Yeung, S., Bakhos, M., Biller, J. Tags: Cerebrovascular Case Reports Source Type: research

Aortic Sarcoma Mimicking a Thrombus Filling Vascular Lumen: A Rare Cause of Cerebral Infarction (P4.364)
Conclusion- Primary aortic sarcoma is an extremely rare cause of stroke. This sarcoma may be misinterpreted as a thrombus filling vascular lumen on CT angiography, but no elevation of D-dimer is incompatible with a large thrombus. The final diagnosis can be made by surgical biopsy.Disclosure: Dr. Kim has nothing to disclose. Dr. Jeon has nothing to disclose. Dr. Park has nothing to disclose. Dr. Kim has nothing to disclose. Dr. Kim has nothing to disclose. Dr. Kwon has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Kim, H., Jeon, S.-B., Park, K.-W., Kim, H., Kim, B. J., Kwon, S. Tags: Cerebrovascular Case Reports Source Type: research

Intracranial Hemorrhage on Warfarin: Time to Reversal Is of the Essence (S16.008)
Conclusions: We propose a "recommended reversal time" of less than 200 minutes for Vitamin K antagonists.Disclosure: Dr. Mehta has nothing to disclose. Dr. Jones has nothing to disclose. Dr. Ruiz Cuero has nothing to disclose. Dr. Wellwood has nothing to disclose. Dr. Rehman has nothing to disclose. Dr. Mitsias has nothing to disclose. Dr. Varelas has received personal compensation for activities with UCB Pharma as an advisory board member.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Mehta, C., Jones, M., Ruiz Cuero, M., Wellwood, J., Rehman, M., Mitsias, P., Varelas, P. Tags: Prehospital/Emergency Room Stroke Care and Intracerebral Hemorrhage Source Type: research

Analysis of Inpatient Thrombophilia Testing for Adults with an Ischemic Stroke or Transient Ischemic Attack and its Impact on Clinical Management (P1.123)
Conclusions: Inpatient thrombophilia testing did not affect management in the vast majority of patients with an ischemic stroke or TIA despite a positive test result. Therefore, by avoiding inpatient testing, healthcare costs may be reduced without affecting patient care.Disclosure: Dr. Gavva has nothing to disclose. Dr. Alberts has received personal compensation for activities with AGA medical, AstraZeneca, Bayer, Pfizer, Bistol-Myers-Squibb, Boehringer Ingelheim, diaDexus, Genentech, KOS, Medicine Company, PDL biopharma, Pfizer, Photothera, Sanofi. Dr. Johnson has nothing to disclose. Dr. Sarode has received personal com...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Gavva, C., Alberts, M., Johnson, M., Sarode, R. Tags: Cerebrovascular Disease: Epidemiology Source Type: research

Antithrombotic Strategy in Cerebral Venous Thrombosis: Differences Between Neurologists and Haematologists in a Canadian Survey (I2.010)
Conclusions: In this cohort, there are differences between neurologists and hematologists with regards to initial choice of anticoagulant. It is possible that more complex presenting cases of CVT with concurrent venous infarction, hemorrhage or seizure may present to neurologists as compared to hematologists. Thus, an initial preference for UFH may reflect a desire for a reversible agent with a short half-life in the event of bleeding complications in an unstable patient. Our study is limited by response bias, though our response rate of 28[percnt] is comparable to other contemporary web-based physician surveys. The majori...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Alshimemeri, S., Camden, M.-C., Lui, G., Lee, A., Field, T. Tags: Stroke in the Elderly and Young: Challenges for the Next Decade Poster Presentations Source Type: research

Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type
Conclusions: In this small prospective observational study, patients with NOAC-associated ICH had smaller ICH volumes and better clinical outcomes compared with warfarin-associated ICH.
Source: Neurology - January 25, 2016 Category: Neurology Authors: Wilson, D., Charidimou, A., Shakeshaft, C., Ambler, G., White, M., Cohen, H., Yousry, T., Al-Shahi Salman, R., Lip, G. Y. H., Brown, M. M., Jager, H. R., Werring, D. J., On behalf of the CROMIS-2 collaborators Tags: Prognosis, Clinical trials Observational study (Cohort, Case control), Intracerebral hemorrhage ARTICLE Source Type: research

Clinical Reasoning: A 68-year-old man with a history of lung cancer presenting with right-sided weakness and aphasia
A 68-year-old man with paroxysmal atrial fibrillation on warfarin, left subclavian thrombosis treated with carotid-subclavian bypass, and lung adenocarcinoma treated with pneumonectomy, chemotherapy, and prophylactic cranial irradiation and in remission since 1987 was admitted to our neurocritical care unit with acute onset of right-sided weakness, expressive aphasia, and lethargy. On admission his temperature was 101.7°F, and initial blood pressure was 140/60 mm Hg. There was no nuchal rigidity. He was alert and mute with impaired comprehension. He had left gaze preference. Vision was impaired in the right field. Ther...
Source: Neurology - October 5, 2015 Category: Neurology Authors: Gupta, A., Etherton, M. R., McKee, K., Baker, J. M., Izzy, S., Feske, S. K. Tags: All Cerebrovascular disease/Stroke, Radiation therapy-tumor, All Epilepsy/Seizures RESIDENT AND FELLOW SECTION Source Type: research

Potential new uses of non-vitamin K antagonist oral anticoagulants to treat and prevent stroke
Conclusion: There may be a role for NOACs in stroke prevention and treatment beyond atrial fibrillation. Randomized controlled trials are needed to compare NOACs to current stroke prevention and treatment strategies in certain subgroups of patients with cerebrovascular disease.
Source: Neurology - September 21, 2015 Category: Neurology Authors: Yaghi, S., Kamel, H., Elkind, M. S. V. Tags: Stroke prevention, All Cerebrovascular disease/Stroke, Infarction, Cerebral venous thrombosis VIEWS & amp;amp; REVIEWS Source Type: research

Pages: 1  2  3  4  5